BTIG Remains Neutral on Juno Therapeutics (JUNO); Says JCAR015 Will Have 'Limited Impact' on Ests
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
The firm commented today,
This follows the FDA mandated clinical hold back in July after several patients died in the ROCKET study, but the trial hold was lifted after a week with a protocol change to eliminate fludarabine preconditioning. Expectations for JCAR015 were reduced after the first clinical hold, so although today’s announcement will be a negative for sentiment on JUNO heading into ASH, it has limited impact on our financial estimates.
We think that the JCAR015 program will be terminated, with the ROCKET study for Adult ALL being the lead study. Management is still evaluating strategic options, and may see a path forward but would not commit to a decision on the call with investors.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galena Biopharma (GALE) PT Raised to $4 at Maxim Group into San Antonio Breast Cancer Symposium
- Jefferies Raises Price Target on Ulta Salon (ULTA) to $270; Reiterates Hold
- Jefferies Raises Price Target on US Physical Therapy (USPH) to $63 Following 12-Clinic Acquisition
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!